珠贝定喘丸联合沙美特罗替卡松治疗儿童支气管哮喘的疗效观察

目的 探讨珠贝定喘丸联合沙美特罗替卡松治疗儿童支气管哮喘的临床效果。方法 选取2016年9月-2018年9月河南科技大学第一附属医院（开元院区）收治的支气管哮喘患儿116例，随机分为对照组（58例）和治疗组（58例）。对照组吸入沙美特罗替卡松气雾剂，1揿/次，1次/d；治疗组患儿在对照组的基础上口服珠贝定喘丸，3~4岁儿童1丸/次，5~6岁2丸/次，7~8岁3丸/次，9~10岁4丸/次，11~13岁5丸/次，3次/d。两组患儿连续治疗3个月。观察两组患者临床疗效，同时比较治疗前后两组患者症状和体征消失时间，肺功能指标一秒用力呼气容积（FEV₁）、用力肺活量（FVC）和FEV₁/FVC，及血气指标血氧分压（pO₂）和二氧化碳分压（pCO₂）。结果 治疗后，对照组和治疗组临床有效率分别为84.48%和96.55%，两组比较差异具有统计学意义（P<0.05）。治疗组患儿症状、体征消失时间均明显短于对照组（P<0.05）。治疗后，两组FEV₁、FVC、FEV₁/FVC均显著升高（P<0.05），且治疗组明显高于对照组（P<0.05）。治疗后，两组患儿pO₂明显升高（P<0.05），而pCO₂明显降低（P<0.05）；且治疗组患儿pO₂和pCO₂明显好于对照组（P<0.05）。结论 珠贝定喘丸联合沙美特罗替卡松治疗小儿支气管哮喘可显著提升疗效，有助于改善肺功能并缩短病程时间，且安全性较高。

Clinical observation of Zhubei Dingchuan Pills combined with salmeterol xinafoate and fluticasone propionate in treatment of bronchial asthma in children

Objective To investigate the clinical effect of Zhubei Dingchuan Pills combined with salmeterol xinafoate and fluticasone propionate in treatment of bronchial asthma in children. Methods Children (116 cases) with bronchial asthma in the First Affiliated Hospital of Henan University of Science and Technology (Kaiyuan District) from September 2016 to September 2018 were randomly divided into control (58 cases) and treatment (58 cases) groups. Children in the control group were inhalation administered with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation, 1 press/time, once daily. Children in the treatment group were po administered with Zhubei Dingchuan Pills on the basis of the control group, 1 pill/time for 3-4 years old, 2 pills/time for 5-6 years old, 3 pills/time for 7-8 years old, 4 pills/time for 9-10 years old, 5 pills/time for 11-13 years old, three times daily. Children in two groups were treated for 90 d. After treatment, the clinical efficacy was evaluated, and the disappearance time of symptoms and signs, the lung function indexes of FEV₁, FVC and FEV₁/FVC, the blood and gas indexes of pO₂ and pCO₂ in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 84.48% and 96.55% respectively, and there were differences between two groups (P<0.05). After treatment, the disappearance time of symptoms and signs in the treatment group was significantly shorter than that in the control group (P<0.05). After treatment, the indexes of FEV₁, FVC and FEV₁/FVC in two groups were significantly increased (P<0.05), and which in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the pO₂ levels in two groups were significantly increased (P<0.05), but the pCO₂ levels in two groups were significantly decreased (P<0.05), and the pO₂, pCO₂ in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Zhubei Dingchuan Pills combined with salmeterol xinafoate and fluticasone propionate in treatment of bronchial asthma in children can significantly increase the efficacy with high safety, improve the lung function and shorten the duration of the disease.